Treating Radioactive Iodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) with Lenvatinib - Episode 2

NCCN Guideline Updates on Lenvatinib for the Treatment of Advanced RAI-R-DTC

Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.